Clinical breast cancer · 2026
Retrospective Analysis of Acute Toxicity Following Breast Cancer Re-Irradiation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Alyssa Jiaxin, Kagan Shely, Zhang Liying, Hircock Caroline, Bayrakdarian Sarah, Chen Hanbo, Vesprini Danny, Soliman Hany, Chow Edward, Karam Irene
Аннотация
PURPOSE: To evaluate the acute skin toxicity and treatment-related factors in patients undergoing breast re-irradiation in a tertiary cancer centre.
METHODS: A retrospective review was conducted of patients who received a repeat course of breast or chest wall radiation for ipsilateral breast cancer recurrence between April 20, 2011, and December 31, 2023. Patient characteristics, treatment parameters, and clinician-graded acute toxicity were recorded. Associations between toxicity and treatment factors were analyzed.
RESULTS: Seventy patients met inclusion criteria. Acute skin toxicity was lower during retreatment than initial treatment with 22.9% of patients (n = 16) developing moderate/severe reactions during re-irradiation compared with 51.4% (n = 36) during the initial course. Severe toxicity at retreatment was not common, including moist desquamation in 10 patients (14.3%). Toxicity during the initial course did not predict toxicity during re-irradiation (P = .75). Across all fractionation schedules, no significant associations were observed between dose regimen and symptoms such as pruritus, pain, erythema, discoloration, edema, burning, dry desquamation or moist desquamation.
CONCLUSIONS: Breast re-irradiation was well tolerated in the acute setting, with toxicity patterns influenced primarily by radiation dose and delivery. The findings emphasize the need for ongoing prospective work to assess long-term outcomes.
METHODS: A retrospective review was conducted of patients who received a repeat course of breast or chest wall radiation for ipsilateral breast cancer recurrence between April 20, 2011, and December 31, 2023. Patient characteristics, treatment parameters, and clinician-graded acute toxicity were recorded. Associations between toxicity and treatment factors were analyzed.
RESULTS: Seventy patients met inclusion criteria. Acute skin toxicity was lower during retreatment than initial treatment with 22.9% of patients (n = 16) developing moderate/severe reactions during re-irradiation compared with 51.4% (n = 36) during the initial course. Severe toxicity at retreatment was not common, including moist desquamation in 10 patients (14.3%). Toxicity during the initial course did not predict toxicity during re-irradiation (P = .75). Across all fractionation schedules, no significant associations were observed between dose regimen and symptoms such as pruritus, pain, erythema, discoloration, edema, burning, dry desquamation or moist desquamation.
CONCLUSIONS: Breast re-irradiation was well tolerated in the acute setting, with toxicity patterns influenced primarily by radiation dose and delivery. The findings emphasize the need for ongoing prospective work to assess long-term outcomes.